Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis
Collection of Blood From Therapeutic Trial Participants for Analysis of Genetic Differences in Drug Disposition and Pharmacokinetics of Probe Medications
2 other identifiers
observational
1,100
1 country
1
Brief Summary
Background: \- Some genes may be associated with a greater chance of side effects during cancer treatment. These genes may also make certain treatments less effective. Researchers want to collect blood or cheek swab samples from people having cancer treatment to study these genes. Objectives: \- To obtain a blood or cheek swab sample to study genetic differences that may affect cancer treatment. Eligibility: \- Individuals with cancer who are being treated at the National Cancer Institute. Design:
- Participants will provide a blood sample for study.
- Participants who have blood-based cancer, such as leukemia, will provide a cheek swab sample.
- If the blood or cheek swab sample does not have enough genetic material for analysis, an additional sample may be collected.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
September 24, 2011
CompletedFirst Posted
Study publicly available on registry
September 27, 2011
CompletedStudy Start
First participant enrolled
May 21, 2012
CompletedApril 14, 2026
January 23, 2026
September 24, 2011
April 11, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Obtain and analyze the genomic DNA from patients with cancer, other tumors, or possible genetic tumor predisposition syndromes on a therapeutic clinical trial.
to determine the association between SNP parameters and clinical response and/or toxicity from genomic DNA extracted from patient samples
duration of study
Study Arms (1)
1/ Patients with cancer, other tumors, or possible genetic tumor
Patients enrolled on IRB approved NIH Intramural Research Program (IRP) therapeutic clinical trials
Eligibility Criteria
Any patient enrolled on an IRB approved NIH Intramural Research Program therapeutic clinical trial with cancer, other tumors, or possible genetic tumor predisposition syndromes.
You may qualify if:
- Any individual currently enrolled in an NIH intramural research program clinical trials receiving treatment.
- Ability of participant or Legally Authorized Representative (LAR) to understand and be willing to sign the informed consent document.
- Age \>= 3 years old
You may not qualify if:
- N/A
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
Related Links
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
William D Figg, Pharm.D.
National Cancer Institute (NCI)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- CASE ONLY
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- NIH
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
September 24, 2011
First Posted
September 27, 2011
Study Start
May 21, 2012
Last Updated
April 14, 2026
Record last verified: 2026-01-23
Data Sharing
- IPD Sharing
- Will share
- Shared Documents
- STUDY PROTOCOL, SAP, ICF
- Time Frame
- Data from this study may be requested from other researchers after the completion of the primary endpoint.
- Access Criteria
- Data from this study may be requested by contacting the PI
All collected IPD will be shared